Analyst firms · H.C. Wainwright · CHRS
H.C. Wainwright CHRS price target and rating history
Coherus Oncology Inc. (CHRS) · Health Care
H.C. Wainwright rates Coherus Oncology Inc. (CHRS) Buy with a $7 price target, as of its latest action on Oct 29, 2026. It has published 3 rating actions on CHRS since July 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a CHRS price target in the last 12 months, the median target is $10. H.C. Wainwright's $7 is 30% below that.
- Current rating
- Buy
- Price target
- $7
- Median target, all firms
- $10
- Actions on CHRS
- 3
H.C. Wainwright price target on CHRS
Every H.C. Wainwright rating on CHRS
- Oct 29, 2026
- Nov 9, 2021
- Jul 23, 2021
How other firms rate CHRS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $7 | Oct 29, 2026 |
| Guggenheim | Buy | $12 | May 11, 2026 |
| Oppenheimer | Outperform | $10 | Jan 23, 2026 |
Questions about H.C. Wainwright and CHRS
- What is H.C. Wainwright's price target for CHRS?
- H.C. Wainwright's latest stated price target for Coherus Oncology Inc. (CHRS) is $7, from its action on Oct 29, 2026.
- What is H.C. Wainwright's rating on CHRS?
- H.C. Wainwright rates CHRS Buy, a bullish rating, as of Oct 29, 2026.
- When did H.C. Wainwright last change its view on CHRS?
- On Oct 29, 2026, H.C. Wainwright resumes coverage at Buy, price target $7.
- How does H.C. Wainwright's CHRS target compare with other analysts?
- Across 3 firms with a CHRS price target in the last 12 months, the median target is $10. H.C. Wainwright's $7 is 30% below that.
More CHRS rating histories
All H.C. Wainwright ratingsCHRS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.